Safety, pharmacokinetics and neutralization of the broadly neutralizing HIV-1 human monoclonal antibody VRC01 in healthy adults

被引：217

作者：

Ledgerwood, J. E. ^{[1
]}

Coates, E. E. ^{[1
]}

Yamshchikov, G. ^{[1
]}

Saunders, J. G. ^{[1
]}

Holman, L. ^{[1
]}

Enama, M. E. ^{[1
]}

DeZure, A. ^{[1
]}

Lynch, R. M. ^{[1
]}

Gordon, I. ^{[1
]}

Plummer, S. ^{[1
]}

Hendel, C. S. ^{[1
]}

Pegu, A. ^{[1
]}

Conan-Cibotti, M. ^{[1
]}

Sitar, S. ^{[1
]}

Bailer, R. T. ^{[1
]}

Narpala, S. ^{[1
]}

McDermott, A. ^{[1
]}

Louder, M. ^{[1
]}

O'Dell, S. ^{[1
]}

Mohan, S. ^{[2
]}

Pandey, J. P. ^{[2
]}

Schwartz, R. M. ^{[1
]}

Hu, Z. ^{[3
]}

Koup, R. A. ^{[1
]}

Capparelli, E. ^{[4
,5
]}

Mascola, J. R. ^{[1
]}

Graham, B. S. ^{[1
]}

机构：

[1] NIAID, VRC, NIH, Bethesda, MD 20892 USA

[2] Med Univ S Carolina, Dept Microbiol & Immunol, Charleston, SC 29425 USA

[3] NIAID, Biostat Res Branch, Div Clin Res, NIH, Bethesda, MD 20892 USA

[4] Univ Calif San Diego, Sch Med, San Diego, CA 92103 USA

[5] Univ Calif San Diego, Skaggs Sch Pharm & Pharmaceut Sci, San Diego, CA 92103 USA

来源：

CLINICAL AND EXPERIMENTAL IMMUNOLOGY | 2015年 / 182卷 / 03期

基金：

美国国家卫生研究院;

关键词：

HIV-1; monoclonal antibody; pharmacokinetics; Phase I clinical trial; passive immunization; IMMUNODEFICIENCY-VIRUS TYPE-1; CD4-BINDING SITE; HIV-1-INFECTED HUMANS; STRUCTURAL BASIS; GAMMA-GLOBULIN; IMMUNIZATION; EXPRESSION; MATURATION; GENERATION; PROTECTION;

D O I：

10.1111/cei.12692

中图分类号：

R392 [医学免疫学]; Q939.91 [免疫学];

学科分类号：

100102 ;

摘要：

VRC-HIVMAB060-00-AB (VRC01) is a broadly neutralizing HIV-1 monoclonal antibody (mAb) isolated from the B cells of an HIV-infected patient. It is directed against the HIV-1 CD4 binding site and is capable of potently neutralizing the majority of diverse HIV-1 strains. This Phase I dose-escalation study in healthy adults was conducted at the National Institutes of Health (NIH) Clinical Center (Bethesda, MD, USA). Primary objectives were the safety, tolerability and pharmacokinetics (PK) of VRC01 intravenous (i.v.) infusion at 5, 20 or 40mg/kg, given either once (20mg/kg) or twice 28days apart (all doses), and of subcutaneous (s.c.) delivery at 5mg/kg compared to s.c. placebo given twice, 28days apart. Cumulatively, 28 subjects received 43 VRC01 and nine received placebo administrations. There were no serious adverse events or dose-limiting toxicities. Mean 28-day serum trough concentrations after the first infusion were 35 and 57g/ml for groups infused with 20mg/kg (n=8) and 40 mg/kg (n=5) doses, respectively. Mean 28-day trough concentrations after the second infusion were 56 and 89 g/ml for the same two doses. Over the 5-40 mg/kg i.v. dose range (n=18), the clearance was 0016l/h and terminal half-life was 15days. After infusion VRC01 retained expected neutralizing activity in serum, and anti-VRC01 antibody responses were not detected. The human monoclonal antibody (mAb) VRC01 was well tolerated when delivered i.v. or s.c. The mAb demonstrated expected half-life and pharmacokinetics for a human immunoglobulin G. The safety and PK results support and inform VRC01 dosing schedules for planning HIV-1 prevention efficacy studies.

引用

页码：289 / 301

页数：13

共 45 条

[1] ANTIBODIES TO GENETIC TYPES OF GAMMA GLOBULIN AFTER MULTIPLE TRANSFUSIONS [J].